Also trades as: RGBP (OTC) · $vol 0M
RGBPP OTC
Regen BioPharma, Inc.
1W: -49.0%
1M: -51.6%
3M: -70.0%
YTD: -91.7%
1Y: -98.3%
3Y: -99.9%
5Y: -100.0%
$0.00
-0.00 (-21.05%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
14 relationships14
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-04-16
Earliest Filing
2025-10-03
Latest Filing
partner: 4
acquirer: 3
investor: 3
customer: 2
supplier: 2
Counterparties (Filed by RGBPP)
14 relationshipsCompanies named in RGBPP's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Regen BioPharma, Inc. | RGBPP | acquirer | Company entering into consulting agreement for Phase I Clinical Trial of HemaXellerate | 2025-10-03 | View |
| Regen Biopharma, Inc. | RGBPP | customer | Issuer of the promissory note and borrower of funds | 2025-08-07 | View |
| CFI CAPITAL LLC | — | investor | Holder of the 6% Convertible Redeemable Note issued by Regen Biopharma, Inc. | 2025-08-01 | View |
| REGEN BIOPHARMA, INC | RGBPP | acquirer | Company issuing securities | 2024-09-13 | View |
| Coventry Enterprises, LLC | — | investor | Investor purchasing Promissory Note | 2024-09-13 | View |
| REGEN BIOPHARMA, INC | RGBPP | acquirer | Company issuing securities | 2023-09-18 | View |
| Coventry Enterprises, LLC | — | investor | Investor purchasing Promissory Note | 2023-09-18 | View |
| Regen Biopharma, Inc. | RGBPP | partner | Issuer of the 5% Promissory Note | 2021-09-24 | View |
| CHEMDIV, INC. | — | customer | Received $800,000 settlement payment from Regen Biopharma, Inc. for services rendered. | 2021-09-16 | View |
| REGEN BIOPHARMA, INC. | RGBPP | supplier | Agreed to pay $800,000 settlement to Chemdiv, Inc. contingent on SEC filing requirements. | 2021-09-16 | View |
| ZANDER THERAPEUTICS, INC. | — | supplier | Joint defendant in litigation with Regen Biopharma, Inc. and subject of service dispute with Chemdiv, Inc. | 2021-09-16 | View |
| Zander Therapeutics, Inc. | — | partner | Counterparty in amendment regarding license agreement and convertible note conversion | 2021-04-16 | View |
| KCL Therapeutics, Inc. | — | partner | Counterparty in amendment; wholly owned subsidiary of Regen | 2021-04-16 | View |
| Regen Biopharma, Inc. | RGBPP | partner | Counterparty in amendment; licensor and issuer of convertible notes | 2021-04-16 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-15 | Material Agreement; Accountant Change; Other Events; Exhibits | Agreement | View |
| 2026-03-04 | Unregistered Sales of Equity Securities | View | |
| 2026-02-02 | Unregistered Sales of Equity Securities | View | |
| 2026-01-21 | Other Events | View | |
| 2025-11-13 | Unregistered Sales of Equity Securities | View | |
| 2025-10-03 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-09-19 | Unregistered Sales of Equity Securities | View | |
| 2025-08-07 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-08-01 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-06-11 | Unregistered Sales of Equity Securities; Financial Statements and Exhibits | View | |
| 2025-05-13 | Non-Reliance on Previously Issued Financial Statements | View | |
| 2025-04-07 | Changes in Registrant's Certifying Accountant | View | |
| 2024-11-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-09-18 | Other Events | View | |
| 2024-09-13 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2024-05-29 | Changes in Registrant's Certifying Accountant | View | |
| 2024-05-23 | Amendments to Articles of Incorporation or Bylaws; Other Events; Financial Statements and Exhibits | View | |
| 2024-04-29 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2024-02-09 | Other Events | View | |
| 2023-09-18 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR